Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
- 19 Guardion devices built, including nine in the first quarter of FY27
- FDA Class II medical device listing expected in the coming weeks
- US partnerships now span blood, cell and gene therapy
- $38.3 million in cash and term deposits at 30 September
- Shareholders approved a 10% placement facility with 94.28% support
Guardion fleet expands ahead of FDA milestone
Vitrafy Life Sciences Limited (ASX:VFY) has put a number on its shift from laboratory promise to commercial execution: 19 Guardion cryopreservation devices had been built by the annual general meeting, including nine in the first quarter of FY27. Managing Director and CEO Brent Owens said six more were forecast for release in the current quarter, taking the fleet to about 25 completed units.
The company expects Guardion to be listed by the US Food and Drug Administration as a Class II medical device in the coming weeks. That would take the system beyond research-use settings and broaden its potential deployment across blood centres, hospitals and cell therapy manufacturing, although the filing describes the milestone as expected rather than completed. Research-use units are currently being deployed with partners and used in verification and validation work.
US blood partnerships move towards commercial conversion
Vitrafy said its US blood network now includes Vitalant, Hoxworth and Versiti, alongside the US Army Institute of Surgical Research. Owens said the relationships represented exposure to approximately 17% of US blood collection sites, with work spanning red cells, platelets and plasma. The company’s latest presentation also reiterated the earlier Versiti partnership, which focused on platelet preservation and regulatory verification rather than immediate revenue.
The commercial sequence remains clear but unfinished: partner, deploy Guardion and LifeChain into the customer’s workflow, then convert successful evaluations into paid adoption and recurring fees. Vitrafy cited independently generated platelet results of 94.4% mean post-thaw recovery from the US Army study as a key reason for rising industry engagement. The company did not disclose revenue from the civilian blood partnerships in these AGM materials.
Capital funds manufacturing and Colorado expansion
Vitrafy raised $32 million through a $30 million placement in June and a $2 million share purchase plan in July. It reported $38.3 million in cash and term deposits at 30 September, equivalent to about 7.9 quarters of funding at the first-quarter FY27 net operating outflow of $4.9 million. Management also cautioned that near-term costs would continue to rise as it invests in validation, manufacturing, US operations and staff, so the stated runway is not a fixed forecast.
The company plans to manufacture its first medical-device fleet in Australia in early 2027, with US manufacturing targeted for the second half of calendar 2027. Owens is relocating to Colorado, where Vitrafy is establishing its US operating base, while Jan Gielen is due to become chief financial officer on 1 February 2027. The company also highlighted its first US cell and gene therapy agreement with Charter Medical and a partnership with IMV Technologies in animal reproduction, which it said is already generating recurring revenue.
Shareholders back board and capital resolutions
The AGM voting figures showed strong support for the formal resolutions presented. Jeannette Joughin was backed for election and Kate Munnings for re-election, while a resolution approving 287,490 performance rights for Owens received 99.92% support among the recorded votes. Shareholders also ratified the prior issue of 11,538,462 placement shares with 97.28% support.
A proposed 10% placement facility attracted 94.28% support, preserving the company’s ability to issue additional equity under the ASX framework, subject to the relevant conditions. That flexibility may assist the commercial build-out, but it also leaves a potential dilution pathway alongside the company’s existing investment program. The immediate operational question is whether the planned FDA listing and device deployments can move the partnership pipeline from evaluation into contracted revenue before further capital is needed.
Bottom Line?
Vitrafy has assembled the devices, partnerships and funding for its US push; the next value test is evidence of FDA listing and paid customer conversion.
Questions in the middle?
- Will the Guardion FDA Class II listing arrive within the company’s stated coming-weeks timeframe?
- How quickly will Vitalant, Hoxworth, Versiti and Charter Medical evaluations convert into commercial contracts and recurring revenue?
- Can the planned Australian and US manufacturing ramp be funded from existing cash before additional equity is required?